AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

The crown jewel of AbbVie’s big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to Evolus’ chances at a major competitor late last year, AbbVie is now putting the icing on the cake.